Global Fabry disease - 2024 -2031
Fabry Disease Treatment Market Size
The Global Fabry Disease Treatment Market size reached USD 1,876.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,287.2 million by 2031. The global Fabry disease treatment market is expected to exhibit a CAGR of 7.4% during the forecast period (2024-2031). The key market trend is the emergence of precision medicine and personalized therapies.
For instance, in May 2023, 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, the Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases such as ophthalmology, pulmonology, and cardiology (Fabry disease cardiomyopathy).
Fabry disease, also known as Anderson-Fabry disease, is a rare genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. It is caused by mutations in the GLA gene, which results in a deficiency or malfunction of the enzyme alpha-galactosidase A (AGA). This enzyme is responsible for breaking down a fatty substance called globotriaosylceramide (Gb3) within cells.
The Fabry disease treatment market is driven by factors such as increasing awareness and diagnosis, increasing demand for novel therapies such as chaperone therapies and enzyme replacement therapies, advancements in treatment options, increasing R&D activities, and technological advancements.
For instance, in February 2023, The novel recombinant human ?–Galactosidase–A (?–Gal–A) enzyme is being investigated as a PEGylated enzyme replacement therapy (ERT) for Fabry disease. The treatment is intended to help address unmet medical needs for these patients, such as progressive kidney decline.
Fabry Disease Treatment Market Dynamics
Increasing Demand for Novel Therapies
The increasing demand for novel therapies such as chaperone therapies and enzyme replacement therapies are the major factors driving the market share during the forecast period. Chaperone therapies, also known as pharmacological chaperone therapies, offer a personalized treatment approach for Fabry disease by targeting specific genetic mutations.
These therapies aim to stabilize and enhance the function of the patient's own defective enzyme, enabling it to effectively break down the accumulated substances. The demand for chaperone therapies is increasing due to their potential benefits in addressing the underlying molecular defects associated with specific mutations, leading to improved treatment outcomes.
High Cost of the Treatment and Limited Treatment Options
The high cost of the treatment and limited treatment options are the major factors hampering the market growth during the forecast period. Fabry disease treatments, including enzyme replacement therapies (ERT) and chaperone therapies, can be expensive. The high cost of these therapies may pose financial challenges for patients, healthcare systems, and payers. Affordability concerns can limit patient access and uptake of treatments, impacting market demand.
Fabry disease patients who have advanced disease manifestations or organ damage may have limited treatment options. Existing therapies may not fully address the complexities and challenges associated with the advanced stages of the disease. The lack of effective treatments for advanced cases can limit market growth and patient outcomes.
Fabry Disease Treatment Market Segment Analysis
The global Fabry disease treatment market is segmented based on drugs, treatment, route of administration, distribution channel, and region.
Based on Treatment, the Enzyme Replacement Therapy (ERT) Segment is Expected to Dominate the Market Share
Based on the treatment, the enzyme replacement therapy (ERT) segment is expected to dominate the market share during the forecast period. The market for enzyme replacement therapy holds the 65.2% of the market share in 2022. ERT has been widely used and accepted as a standard treatment for Fabry disease for many years.
It has a proven track record of effectiveness in reducing symptoms, improving quality of life, and slowing disease progression. The long-standing use and established efficacy of ERT have contributed to its dominance in the market.
Fabry Disease Treatment Market Geographical Share
North America Holds the Largest Market Share Due to the Increasing Adoption of Novel Therapies and the Presence of a Strong Healthcare Infrastructure
North America holds the largest market share during the forecast period due to the increasing adoption of novel therapies and the presence of strong healthcare infrastructure. The region holds the 43.2% market share for the Fabry disease treatment market in 2022.
North America, particularly the United States, has a relatively higher healthcare expenditure compared to other regions. The increased healthcare spending provides better access to advanced treatments, including novel therapies, for Fabry disease patients. The higher healthcare expenditure positively impacts market growth and the adoption of innovative treatments in North America.
Fabry Disease Treatment Market Key Players
The major global players include Sanofi S.A, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Amicus Therapeutics Inc., Amgen Inc., Bristol-Myers Squibb Company, Neuraltus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and Idorsia Pharmaceuticals Ltd.
COVID-19 Impact on Fabry Disease Treatment Market
The COVID-19 pandemic has had a significant impact on the Fabry disease treatment market. The pandemic led to disruptions in healthcare services worldwide. Hospitals and healthcare facilities were overwhelmed with COVID-19 patients, and resources were redirected to address the immediate crisis. This diversion of resources and focus on pandemic management resulted in a temporary disruption of routine medical services, including the diagnosis and treatment of rare diseases like Fabry disease.
The economic impact of the COVID-19 pandemic resulted in financial challenges for healthcare systems, patients, and payers. Affordability concerns may have influenced treatment decisions and market dynamics.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the Fabry disease treatment market growth. The Russia-Ukraine conflict may indirectly impact research and development activities related to Fabry disease treatments. Institutions and organizations involved in research collaborations or clinical trials that have a presence in conflict-affected areas may face challenges in conducting studies, accessing funding, or collaborating with international partners.
Geopolitical conflicts can affect global investor confidence and risk perceptions. If the conflict creates broader market uncertainties, investors may become more cautious and risk-averse. This could potentially impact investments in healthcare companies involved in the development and commercialization of Fabry disease treatments.
Key Developments
Target Audience 2024
The Global Fabry Disease Treatment Market size reached USD 1,876.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 3,287.2 million by 2031. The global Fabry disease treatment market is expected to exhibit a CAGR of 7.4% during the forecast period (2024-2031). The key market trend is the emergence of precision medicine and personalized therapies.
For instance, in May 2023, 4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, the Company is initially focused on five clinical-stage product candidates in three therapeutic areas for both rare and large market diseases such as ophthalmology, pulmonology, and cardiology (Fabry disease cardiomyopathy).
Fabry disease, also known as Anderson-Fabry disease, is a rare genetic disorder that belongs to a group of conditions known as lysosomal storage disorders. It is caused by mutations in the GLA gene, which results in a deficiency or malfunction of the enzyme alpha-galactosidase A (AGA). This enzyme is responsible for breaking down a fatty substance called globotriaosylceramide (Gb3) within cells.
The Fabry disease treatment market is driven by factors such as increasing awareness and diagnosis, increasing demand for novel therapies such as chaperone therapies and enzyme replacement therapies, advancements in treatment options, increasing R&D activities, and technological advancements.
For instance, in February 2023, The novel recombinant human ?–Galactosidase–A (?–Gal–A) enzyme is being investigated as a PEGylated enzyme replacement therapy (ERT) for Fabry disease. The treatment is intended to help address unmet medical needs for these patients, such as progressive kidney decline.
Fabry Disease Treatment Market Dynamics
Increasing Demand for Novel Therapies
The increasing demand for novel therapies such as chaperone therapies and enzyme replacement therapies are the major factors driving the market share during the forecast period. Chaperone therapies, also known as pharmacological chaperone therapies, offer a personalized treatment approach for Fabry disease by targeting specific genetic mutations.
These therapies aim to stabilize and enhance the function of the patient's own defective enzyme, enabling it to effectively break down the accumulated substances. The demand for chaperone therapies is increasing due to their potential benefits in addressing the underlying molecular defects associated with specific mutations, leading to improved treatment outcomes.
High Cost of the Treatment and Limited Treatment Options
The high cost of the treatment and limited treatment options are the major factors hampering the market growth during the forecast period. Fabry disease treatments, including enzyme replacement therapies (ERT) and chaperone therapies, can be expensive. The high cost of these therapies may pose financial challenges for patients, healthcare systems, and payers. Affordability concerns can limit patient access and uptake of treatments, impacting market demand.
Fabry disease patients who have advanced disease manifestations or organ damage may have limited treatment options. Existing therapies may not fully address the complexities and challenges associated with the advanced stages of the disease. The lack of effective treatments for advanced cases can limit market growth and patient outcomes.
Fabry Disease Treatment Market Segment Analysis
The global Fabry disease treatment market is segmented based on drugs, treatment, route of administration, distribution channel, and region.
Based on Treatment, the Enzyme Replacement Therapy (ERT) Segment is Expected to Dominate the Market Share
Based on the treatment, the enzyme replacement therapy (ERT) segment is expected to dominate the market share during the forecast period. The market for enzyme replacement therapy holds the 65.2% of the market share in 2022. ERT has been widely used and accepted as a standard treatment for Fabry disease for many years.
It has a proven track record of effectiveness in reducing symptoms, improving quality of life, and slowing disease progression. The long-standing use and established efficacy of ERT have contributed to its dominance in the market.
Fabry Disease Treatment Market Geographical Share
North America Holds the Largest Market Share Due to the Increasing Adoption of Novel Therapies and the Presence of a Strong Healthcare Infrastructure
North America holds the largest market share during the forecast period due to the increasing adoption of novel therapies and the presence of strong healthcare infrastructure. The region holds the 43.2% market share for the Fabry disease treatment market in 2022.
North America, particularly the United States, has a relatively higher healthcare expenditure compared to other regions. The increased healthcare spending provides better access to advanced treatments, including novel therapies, for Fabry disease patients. The higher healthcare expenditure positively impacts market growth and the adoption of innovative treatments in North America.
Fabry Disease Treatment Market Key Players
The major global players include Sanofi S.A, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd., Amicus Therapeutics Inc., Amgen Inc., Bristol-Myers Squibb Company, Neuraltus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., and Idorsia Pharmaceuticals Ltd.
COVID-19 Impact on Fabry Disease Treatment Market
The COVID-19 pandemic has had a significant impact on the Fabry disease treatment market. The pandemic led to disruptions in healthcare services worldwide. Hospitals and healthcare facilities were overwhelmed with COVID-19 patients, and resources were redirected to address the immediate crisis. This diversion of resources and focus on pandemic management resulted in a temporary disruption of routine medical services, including the diagnosis and treatment of rare diseases like Fabry disease.
The economic impact of the COVID-19 pandemic resulted in financial challenges for healthcare systems, patients, and payers. Affordability concerns may have influenced treatment decisions and market dynamics.
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war significantly impacted the Fabry disease treatment market growth. The Russia-Ukraine conflict may indirectly impact research and development activities related to Fabry disease treatments. Institutions and organizations involved in research collaborations or clinical trials that have a presence in conflict-affected areas may face challenges in conducting studies, accessing funding, or collaborating with international partners.
Geopolitical conflicts can affect global investor confidence and risk perceptions. If the conflict creates broader market uncertainties, investors may become more cautious and risk-averse. This could potentially impact investments in healthcare companies involved in the development and commercialization of Fabry disease treatments.
Key Developments
- In May 2023, Sangamo Therapeutics, Inc., a genomic medicine company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease.
- In May 2023, Protalix BioTherapeutics, a biopharmaceutical company, and Chiesi Group, a specialty pharmaceutical company developed a drug called Elfabrio is approved by FDA for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.
- To visualize the global Fabry disease treatment market segmentation based on drugs, treatment, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of Fabry disease treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drugs
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Novel Therapies
4.1.1.2. Increasing R&D Activities
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.2.2. Limited treatment options
4.1.3. Opportunity
4.1.3.1. Advancements in Treatment Options
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY DRUGS
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Agalsidase Beta (Fabrazyme/Replagal)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Migalastat (Galafold)
7.4. Others
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Enzyme Replacement Therapy (ERT)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chaperone Treatment
8.4. Substrate Reduction Therapy (SRT)
8.5. Others
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Sanofi S.A.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Takeda Pharmaceutical Company Ltd
13.3. Teva Pharmaceutical Industries Ltd.
13.4. Amicus Therapeutics Inc.
13.5. Amgen Inc.
13.6. Bristol-Myers Squibb Company
13.7. Neuraltus Pharmaceuticals Inc.
13.8. Novartis AG
13.9. Pfizer Inc.
13.10. Idorsia Pharmaceuticals Ltd. (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drugs
3.2. Snippet by Treatment
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Novel Therapies
4.1.1.2. Increasing R&D Activities
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment
4.1.2.2. Limited treatment options
4.1.3. Opportunity
4.1.3.1. Advancements in Treatment Options
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. BY DRUGS
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
7.1.2. Market Attractiveness Index, By Drugs
7.2. Agalsidase Beta (Fabrazyme/Replagal)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Migalastat (Galafold)
7.4. Others
8. BY TREATMENT
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Enzyme Replacement Therapy (ERT)*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chaperone Treatment
8.4. Substrate Reduction Therapy (SRT)
8.5. Others
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Others
10. BY DISTRIBUTION CHANNEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Sanofi S.A.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Takeda Pharmaceutical Company Ltd
13.3. Teva Pharmaceutical Industries Ltd.
13.4. Amicus Therapeutics Inc.
13.5. Amgen Inc.
13.6. Bristol-Myers Squibb Company
13.7. Neuraltus Pharmaceuticals Inc.
13.8. Novartis AG
13.9. Pfizer Inc.
13.10. Idorsia Pharmaceuticals Ltd. (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)
Table 2 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)
Table 3 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)
Table 4 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)
Table 5 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 6 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)
Table 7 Global Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 8 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)
Table 9 Global Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 10 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)
Table 11 Global Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 12 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)
Table 13 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 14 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 15 Global Fabry Disease Treatment Market Value, By Region, 2022-2031 (US$ Million)
Table 16 North America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 17 North America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 18 North America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 19 North America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 20 North America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 21 South America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 22 South America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 23 South America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 24 South America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 25 South America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 26 Europe Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 27 Europe Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 28 Europe Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 29 Europe Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 30 Europe Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 31 Asia-Pacific Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 32 Asia-Pacific Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 33 Asia-Pacific Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 34 Asia-Pacific Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 35 Asia-Pacific Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 36 Middle East & Africa Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 37 Middle East & Africa Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 38 Middle East & Africa Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 39 Middle East & Africa Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 40 Sanofi S.A.: Overview
Table 41 Sanofi S.A.: Product Portfolio
Table 42 Sanofi S.A.: Key Developments
Table 43 Takeda Pharmaceutical Company Ltd: Overview
Table 44 Takeda Pharmaceutical Company Ltd: Product Portfolio
Table 45 Takeda Pharmaceutical Company Ltd: Key Developments
Table 46 Teva Pharmaceutical Industries Ltd.: Overview
Table 47 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 48 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 49 Amicus Therapeutics Inc.: Overview
Table 50 Amicus Therapeutics Inc.: Product Portfolio
Table 51 Amicus Therapeutics Inc.: Key Developments
Table 52 Amgen Inc.: Overview
Table 53 Amgen Inc.: Product Portfolio
Table 54 Amgen Inc.: Key Developments
Table 55 Bristol-Myers Squibb Company: Overview
Table 56 Bristol-Myers Squibb Company: Product Portfolio
Table 57 Bristol-Myers Squibb Company: Key Developments
Table 58 Neuraltus Pharmaceuticals Inc.: Overview
Table 59 Neuraltus Pharmaceuticals Inc.: Product Portfolio
Table 60 Neuraltus Pharmaceuticals Inc.: Key Developments
Table 61 Novartis AG: Overview
Table 62 Novartis AG: Product Portfolio
Table 63 Novartis AG: Key Developments
Table 64 Pfizer Inc.: Overview
Table 65 Pfizer Inc.: Product Portfolio
Table 66 Pfizer Inc.: Key Developments
Table 67 Idorsia Pharmaceuticals Ltd.: Overview
Table 68 Idorsia Pharmaceuticals Ltd.: Product Portfolio
Table 69 Idorsia Pharmaceuticals Ltd.: Key Developments
Table 1 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)
Table 2 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)
Table 3 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)
Table 4 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)
Table 5 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 6 Global Fabry Disease Treatment Market Value, By Drugs, 2023, 2027 & 2031 (US$ Million)
Table 7 Global Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 8 Global Fabry Disease Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)
Table 9 Global Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 10 Global Fabry Disease Treatment Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)
Table 11 Global Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 12 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)
Table 13 Global Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 14 Global Fabry Disease Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)
Table 15 Global Fabry Disease Treatment Market Value, By Region, 2022-2031 (US$ Million)
Table 16 North America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 17 North America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 18 North America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 19 North America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 20 North America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 21 South America Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 22 South America Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 23 South America Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 24 South America Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 25 South America Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 26 Europe Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 27 Europe Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 28 Europe Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 29 Europe Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 30 Europe Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 31 Asia-Pacific Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 32 Asia-Pacific Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 33 Asia-Pacific Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 34 Asia-Pacific Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 35 Asia-Pacific Fabry Disease Treatment Market Value, By Country, 2022-2031 (US$ Million)
Table 36 Middle East & Africa Fabry Disease Treatment Market Value, By Drugs, 2022-2031 (US$ Million)
Table 37 Middle East & Africa Fabry Disease Treatment Market Value, By Treatment, 2022-2031 (US$ Million)
Table 38 Middle East & Africa Fabry Disease Treatment Market Value, By Route of Administration, 2022-2031 (US$ Million)
Table 39 Middle East & Africa Fabry Disease Treatment Market Value, By Distribution Channel, 2022-2031 (US$ Million)
Table 40 Sanofi S.A.: Overview
Table 41 Sanofi S.A.: Product Portfolio
Table 42 Sanofi S.A.: Key Developments
Table 43 Takeda Pharmaceutical Company Ltd: Overview
Table 44 Takeda Pharmaceutical Company Ltd: Product Portfolio
Table 45 Takeda Pharmaceutical Company Ltd: Key Developments
Table 46 Teva Pharmaceutical Industries Ltd.: Overview
Table 47 Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 48 Teva Pharmaceutical Industries Ltd.: Key Developments
Table 49 Amicus Therapeutics Inc.: Overview
Table 50 Amicus Therapeutics Inc.: Product Portfolio
Table 51 Amicus Therapeutics Inc.: Key Developments
Table 52 Amgen Inc.: Overview
Table 53 Amgen Inc.: Product Portfolio
Table 54 Amgen Inc.: Key Developments
Table 55 Bristol-Myers Squibb Company: Overview
Table 56 Bristol-Myers Squibb Company: Product Portfolio
Table 57 Bristol-Myers Squibb Company: Key Developments
Table 58 Neuraltus Pharmaceuticals Inc.: Overview
Table 59 Neuraltus Pharmaceuticals Inc.: Product Portfolio
Table 60 Neuraltus Pharmaceuticals Inc.: Key Developments
Table 61 Novartis AG: Overview
Table 62 Novartis AG: Product Portfolio
Table 63 Novartis AG: Key Developments
Table 64 Pfizer Inc.: Overview
Table 65 Pfizer Inc.: Product Portfolio
Table 66 Pfizer Inc.: Key Developments
Table 67 Idorsia Pharmaceuticals Ltd.: Overview
Table 68 Idorsia Pharmaceuticals Ltd.: Product Portfolio
Table 69 Idorsia Pharmaceuticals Ltd.: Key Developments
LIST OF FIGURES
Figure 1 Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 2 Global Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 3 Global Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 4 Global Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 5 Global Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 6 Global Fabry Disease Treatment Market Share, By Region, 2022 & 2031 (%)
Figure 6 Global Fabry Disease Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)
Figure 7 Agalsidase Beta (Fabrazyme/Replagal) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 8 Migalastat (Galafold) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 9 Global Fabry Disease Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)
Figure 10 Enzyme Replacement Therapy (ERT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 11 Chaperone Treatment Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 12 Substrate Reduction Therapy (SRT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 13 Others Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 14 Global Fabry Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)
Figure 15 Oral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 16 Parenteral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 17 Others Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 18 Global Fabry Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)
Figure 19 Hospitals Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 20 Retail Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 21 Online Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 22 Others Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 23 Global Fabry Disease Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)
Figure 24 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 25 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 26 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 27 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 28 Middle East and Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 29 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 30 North America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 31 North America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 32 North America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 33 North America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 34 North America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 35 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 36 South America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 37 South America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 38 South America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 39 South America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 40 South America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 41 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 42 Europe Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 43 Europe Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 44 Europe Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 45 Europe Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 46 Europe Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 47 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 48 Asia-Pacific Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 49 Asia-Pacific Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 50 Asia-Pacific Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 51 Asia-Pacific Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 52 Asia-Pacific Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 53 Middle East & Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 54 Middle East & Africa Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 55 Middle East & Africa Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 56 Middle East & Africa Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 57 Middle East & Africa Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 58 Sanofi S.A.: Financials
Figure 59 Takeda Pharmaceutical Company Ltd: Financials
Figure 60 Teva Pharmaceutical Industries Ltd.: Financials
Figure 61 Amicus Therapeutics Inc.: Financials
Figure 62 Amgen Inc.: Financials
Figure 63 Bristol-Myers Squibb Company: Financials
Figure 64 Neuraltus Pharmaceuticals Inc.: Financials
Figure 65 Novartis AG: Financials
Figure 66 Pfizer Inc.: Financials
Figure 67 Idorsia Pharmaceuticals Ltd.: Financials
Figure 1 Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 2 Global Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 3 Global Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 4 Global Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 5 Global Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 6 Global Fabry Disease Treatment Market Share, By Region, 2022 & 2031 (%)
Figure 6 Global Fabry Disease Treatment Market Y-o-Y Growth, By Drugs, 2022-2030 (%)
Figure 7 Agalsidase Beta (Fabrazyme/Replagal) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 8 Migalastat (Galafold) Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 9 Global Fabry Disease Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)
Figure 10 Enzyme Replacement Therapy (ERT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 11 Chaperone Treatment Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 12 Substrate Reduction Therapy (SRT) Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 13 Others Treatment in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 14 Global Fabry Disease Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)
Figure 15 Oral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 16 Parenteral Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 17 Others Route of Administration in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 18 Global Fabry Disease Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)
Figure 19 Hospitals Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 20 Retail Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 21 Online Pharmacies Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 22 Others Distribution Channel in Global Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 23 Global Fabry Disease Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)
Figure 24 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 25 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 26 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 27 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 28 Middle East and Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 29 North America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 30 North America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 31 North America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 32 North America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 33 North America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 34 North America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 35 South America Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 36 South America Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 37 South America Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 38 South America Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 39 South America Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 40 South America Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 41 Europe Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 42 Europe Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 43 Europe Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 44 Europe Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 45 Europe Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 46 Europe Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 47 Asia-Pacific Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 48 Asia-Pacific Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 49 Asia-Pacific Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 50 Asia-Pacific Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 51 Asia-Pacific Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 52 Asia-Pacific Fabry Disease Treatment Market Share, By Country, 2022 & 2031 (%)
Figure 53 Middle East & Africa Fabry Disease Treatment Market Value, 2022-2031 (US$ Million)
Figure 54 Middle East & Africa Fabry Disease Treatment Market Share, By Drugs, 2022 & 2031 (%)
Figure 55 Middle East & Africa Fabry Disease Treatment Market Share, By Treatment, 2022 & 2031 (%)
Figure 56 Middle East & Africa Fabry Disease Treatment Market Share, By Route of Administration, 2022 & 2031 (%)
Figure 57 Middle East & Africa Fabry Disease Treatment Market Share, By Distribution Channel, 2022 & 2031 (%)
Figure 58 Sanofi S.A.: Financials
Figure 59 Takeda Pharmaceutical Company Ltd: Financials
Figure 60 Teva Pharmaceutical Industries Ltd.: Financials
Figure 61 Amicus Therapeutics Inc.: Financials
Figure 62 Amgen Inc.: Financials
Figure 63 Bristol-Myers Squibb Company: Financials
Figure 64 Neuraltus Pharmaceuticals Inc.: Financials
Figure 65 Novartis AG: Financials
Figure 66 Pfizer Inc.: Financials
Figure 67 Idorsia Pharmaceuticals Ltd.: Financials
